These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36107306)

  • 1. Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study.
    Matsumoto T; Yuasa A; Miller R; Pritchard C; Ohashi T; Taie A; Gordon J
    Pharmacoecon Open; 2023 Jan; 7(1):65-76. PubMed ID: 36107306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options.
    Barmpouni M; Gordon JP; Miller RL; Pritchard CRJ; Dennis JW; Grammelis V; Rousakis A; Souliotis K; Poulakou G; Daikos GL; Al-Taie A
    Infect Dis Ther; 2023 Feb; 12(2):527-543. PubMed ID: 36544074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom.
    Gordon J; Gheorghe M; Goldenberg S; Miller R; Dennis J; Al-Taie A
    Pharmacoeconomics; 2023 Dec; 41(12):1657-1673. PubMed ID: 37587392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia.
    Gordon JP; Al Taie A; Miller RL; Dennis JW; Blaskovich MAT; Iredell JR; Turnidge JD; Coombs GW; Grolman DC; Youssef J
    Infect Dis Ther; 2023 Jul; 12(7):1875-1889. PubMed ID: 37341866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan.
    Matsumoto T; Darlington O; Miller R; Gordon J; McEwan P; Ohashi T; Taie A; Yuasa A
    J Health Econ Outcomes Res; 2021; 8(2):64-75. PubMed ID: 34703834
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece.
    Barmpouni M; Gordon JP; Miller RL; Dennis JW; Grammelis V; Rousakis A; Souliotis K; Poulakou G; Daikos GL; Al-Taie A
    Infect Dis Ther; 2023 Jul; 12(7):1891-1905. PubMed ID: 37410343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
    Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
    Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study.
    Gordon J; Gheorghe M; Harrison C; Miller R; Dennis J; Steuten L; Goldenberg S; Gandra S; Al-Taie A
    Pharmacoeconomics; 2024 Mar; 42(3):329-341. PubMed ID: 38001394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
    Kongnakorn T; Wagenlehner F; Falcone M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Int J Antimicrob Agents; 2019 Nov; 54(5):633-641. PubMed ID: 31202921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.
    Kamae I; Hashimoto Y; Koretsune Y; Tanahashi N; Murata T; Phatak H; Liu LZ; Tang AC; Feng Wang P; Okumura K
    Clin Ther; 2015 Dec; 37(12):2837-51. PubMed ID: 26608819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children.
    Hoshi SL; Okubo R; Tabuchi K; Seposo X; Shono A; Kondo M
    Vaccine; 2022 Sep; 40(37):5513-5522. PubMed ID: 35965241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
    Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
    BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of ceftazidime/avibactam versus colistin + meropenem for treatment of carbapenemic-resistant enterobacteria infections in Chile].
    Gutiérrez A M; Fandiño C
    Rev Chilena Infectol; 2021 Feb; 38(1):7-14. PubMed ID: 33844786
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.